echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The anti-inflammatory drug secukinumab of Novartis has made a significant breakthrough in the treatment of silver chip arthritis

    The anti-inflammatory drug secukinumab of Novartis has made a significant breakthrough in the treatment of silver chip arthritis

    • Last Update: 2014-09-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Biovalley 2014-9-26 pharmaceutical giant Novartis recently announced that secukinumab, a new generation of anti-inflammatory drug developed by the company, has made breakthrough progress in two clinical phase III studies on the treatment of silver chip arthritis, which also adds chips to the final listing of this drug Secukinumab is an antibody drug for injection, which can block the effect of IL-17A, which plays an important role in the process of inflammation The clinical results showed that secukinumab reached the primary and secondary end points predicted by the researchers Compared with the placebo group, secukinumab can significantly inhibit the progress of silvery arthritis, prevent joint injury and keep skin clean At the same time, Novartis said in previous studies, researchers have proved that the safety of the drug is also satisfactory Novartis is expected to formally submit listing requests to FDA and EU pharmaceutical authorities next year, and secukinumab will officially enter the market in early 2015 Novartis has long believed that its antibody technology can replace existing standard anti TNF therapies such as Enbrel and Humira The efficacy of the latter is often weakened over time It is for this reason that a new treatment continues to appear in the current market of silver chip arthritis drugs, and Novartis hopes to seize this opportunity to develop its strengths in this market However, Novartis is not necessarily the last laugh, because more and more pharmaceutical companies are also there This week, celgene's anti TNF drug otezla was approved for sale In addition, brodalumab, an IL-17A inhibitor jointly developed by Amgen and AstraZeneca, has also achieved good clinical phase III research At the same time, Johnson & Johnson and other companies have their own representative works in this field So it will take time to test who will win the final laugh.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.